Dana-Farber Cancer Institute

Company

Related News

Dana-Farber and Gustave Roussy to Host Fifth Transatlantic Oncology Exchange in March 2026

Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on March 27, 2026, featuring discussions on epigenetic therapies, microbiome-driven immunity, and cellular pathway reprogramming. The event continues collaboration between Dana-Farber and France's Gustave Roussy cancer center with support from L'Institut Servier and Medscape Medical Affairs.

Related Clinical Trials

NCT ID Title Status Phase
NCT07601100

A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant

NOT_YET_RECRUITING PHASE1/PHASE2
NCT07592910

A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

NOT_YET_RECRUITING PHASE2
NCT07569250

Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization

NOT_YET_RECRUITING NA
NCT07563010

Menin-Inhibitor Targeted Maintenance in AML

NOT_YET_RECRUITING PHASE2
NCT07562399

Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda

NOT_YET_RECRUITING NA
NCT07551635

SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

NOT_YET_RECRUITING PHASE2
NCT07548476

Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

NOT_YET_RECRUITING NA
NCT07519200

Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention

NOT_YET_RECRUITING NA
NCT07517666

Genetic Information for Families After Tumor Testing Study

ENROLLING_BY_INVITATION NA
NCT07516405

Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

RECRUITING PHASE1